Amphipathic DNA polymers are promising therapies for the prevention of HIV and genital herpes infections. Recent studies on a panel of such compounds indicated potent activity against HIV binding and entry. This current study was conducted to explore the anti-herpes simplex virus (HSV) activity of the same panel of compounds and to determine their mechanism of activity.
Methods
The anti-HSV activity of a 40-nucleotide degenerate polymer (REP 9), a 40-nucleotide polycytidine amphipathic DNA polymer (REP 9C) and an analogue lacking amphipathic activity (Randomer 3) were compared in plaque reduction assays in the absence or presence of human genital tract secretions; the mechanisms of anti-HSV activity were explored.
Results
REP 9 inhibited HSV infection 10,000-fold, whereas Randomer 3 displayed no anti-HSV activity. The antiviral activity was independent of sequence but was dependent on size: the most potent activity was observed for analogues of 40 nucleotides in length. Mechanistic studies indicated that REP 9 and REP 9C blocked HSV-2 binding and entry, were active when added post-entry, inhibited viral gene expression and blocked HSV-induced apoptosis. Confocal microscopy studies showed rapid delivery of fluorescently tagged REP 9 and REP 9C into human epithelial cells, and delivery was significantly greater in infected cells as compared with uninfected cells. REP 9 exhibited no cytotoxicity and retained anti-HSV activity in the presence of cervicovaginal secretions and when virus was introduced in seminal plasma.
Conclusions
REP 9 and REP 9C represent a novel class of antiviral agents that act by multiple mechanisms. These compounds warrant further development for systemic or topical delivery for the prevention and treatment of HIV and HSV.
References
1.
HolmesK.K., LevineR., WeaverM.Effectiveness of condoms in preventing sexually transmitted infections.Bull World Health Organ2004; 82: 454–461.
2.
WaldA., LangenbergA.G., KrantzE.The relationship between condom use and herpes simplex virus acquisition.Ann Intern Med2005; 143: 707–713.
3.
QuinnT.C.Circumcision and HIV transmission.Curr Opin Infect Dis2007; 20: 33–38.
4.
CheckE.Scientists rethink approach to HIV gels.Nature2007; 446: 12.
5.
StammW.E., HandsfieldH.H., RompaloA.M.The association between genital ulcer disease and acquisition of HIV infection in homosexual men.JAMA1988; 260: 1429–1433.
6.
FreemanE.E., WeissH.A., GlynnJ.R., CrossP.L., WhitworthJ.A., HayesR.J.Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.AIDS2006; 20: 73–83.
7.
NagotN., OuedraogoA., FoulongneV.Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.N Engl J Med2007; 356: 790–799.
MogensenT.H., MelchjorsenJ., MalmgaardL., CasolaA., PaludanS.R.Suppression of proinflammatory cytokine expression by herpes simplex virus type 1.J Virol2004; 78: 5883–5890.
10.
AgrawalS.Antisense oligonucleotides as antiviral agents.Trends Biotechnol1992; 10: 152–158.
11.
AndersonK.P., FoxM.C., Brown-DriverV., MartinM.J., AzadR.F.Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA.Antimicrob Agents Chemother1996; 40: 2004–2011.
12.
FennewaldS.M., MustainS., OjwangJ., RandoR.F.Inhibition of herpes simplex virus in culture by oligonucleotides composed entirely of deoxyguanosine and thymidine.Antiviral Res1995; 26: 37–54.
13.
HokeG.D., DraperK., FreierS.M.Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection.Nucleic Acids Res1991; 19: 5743–5748.
14.
GaoW.Y., HanesR.N., Vazquez-PaduaM.A., SteinC.A., CohenJ.S., ChengY.C.Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides.Antimicrob Agents Chemother1990; 34: 808–812.
15.
GaoW.Y., JaroszewskiJ.W., CohenJ.S., ChengY.C.Mechanisms of inhibition of herpes simplex virus type 2 growth by 28-mer phosphorothioate oligodeoxycytidine.J Biol Chem1990; 265: 20172–20178.
16.
AgrawalS., TangJ.Y., BrownD.M.Analytical study of phosphorothioate analogues of oligodeoxynucleotides using high-performance liquid chromatography.J Chromatogr1990; 509: 396–399.
17.
VaillantA., JuteauJ.M., LuH.Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.Antimicrob Agents Chemother2006; 50: 1393–1401.
JohnM., KellerM.J., FamE.H.Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection.J Infect Dis2005; 192: 1731–1740.
20.
PatelS., HazratiE., CheshenkoN.Seminal plasma reduces the effectiveness of topical polyanionic microbicides.J Infect Dis2007; 196: 1394–1402.
21.
KellerM.J., GuzmanE., HazratiE.PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity.AIDS2007; 21: 467–476.
22.
CheshenkoN., LiuW., SatlinL.M., HeroldB.C.Focal adhesion kinase plays a pivotal role in herpes simplex virus entry.J Biol Chem2005; 280: 31116–31125.
23.
MadanR.P., MesquitaP.M., CheshenkoN.Molecular umbrellas: a novel class of candidate topical microbicides to prevent HIV and HSV infection.J Virol2007; 81: 7637–7646.
24.
LamondA.I., SproatB.S.Antisense oligonucleotides made of 2’-O-alkylRNA: their properties and applications in RNA biochemistry.FEBS Lett1993; 325: 123–127.
25.
MarshallW.S., BeatonG., SteinC.A., MatsukuraM., CaruthersM.H.Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidine.Proc Natl Acad Sci U S A1992; 89: 6265–6269.
26.
PapucciL., SchiavoneN., DonniniM.Phosphodiester oligonucleotides inhibit mitosis and trigger apoptosis by a non-antisense, p53-mediated mechanism.Antisense Nucleic Acid Drug Dev2002; 12: 21–31.
27.
KrakauerD.C., PayneR.J.The evolution of virus-induced apoptosis.Proc Biol Sci1997; 264: 1757–1762.
GianniT., MenottiL., Campadelli-FiumeG.A heptad repeat in herpes simplex virus 1 gH, located downstream of the alpha-helix with attributes of a fusion peptide, is critical for virus entry and fusion.J Virol2005; 79: 7042–7049.
30.
HeroldB.C., WuDunnD., SoltysN., SpearP.G.Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity.J Virol1991; 65: 1090–1098.
31.
CheshenkoN., HeroldB.C.Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread.J Gen Virol2002; 83: 2247–2255.
32.
CheshenkoN., LiuL., SatlinL.M., HeroldB.C.Multiple receptor interactions trigger release of membrane and intracellular calcium stores critical for HSV entry.Mol Biol Cell2007; 18: 3119–3130.
33.
BobardtM.D., ChatterjiU., SelvarajahS.Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells.J Virol2007; 81: 395–405.
